Clinical trial · Interventional
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR Mutations
NCT05025488CI-TRIAL-00088187active not recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| MPN | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
| Myelofibrosis | Primary Myelofibrosis | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Peptide-based vaccine | Drug | — | UNRESOLVED |
| Poly ICLC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CALR mutated
- description
- peptide-based vaccine in patients with myeloproliferative neoplasm (myelofibrosis and essential thrombocythemia) with CALR mutations
- interventionNames
- Drug: Peptide-based vaccine
- Drug: Poly ICLC
Primary outcomes (1)
- measure
- Number of Participants with Dose Limiting Toxicity (DLT)
- timeFrame
- 32 weeks
- description
- The Dose Limiting Toxicity (DLT) rate, defined as the proportion of patients with at least 1 grade 3 or higher AE considered to be at least possibly related to the treatment with Poly ICLC and CALR vaccines.
Secondary outcomes (7)
- measure
- Number of Adverse Events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects must be ≥18 years of age at the time of signing the informed consent form. * Confirmed diagnosis of chronic phase MPN: * Previously treated or relapsed/refectory high risk ET * Low to intermediate 1 risk (DIPSS 0-1) PMF or ET-MF * Verified mutation in CALR exon 9 * PS ≤ 2 * Adequate organ function: * Absolute neutrophil count ≥ 1000/mm3, * Platelet count ≥ 50,000/mm3, * Creatinine ≤ 2.5 mg/dL, * Total bilirubin ≤ 2 mg/dL, (except in patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dL) * Transaminases \< 3 times above the upper limits of the institutional normal. * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting study medication and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks prior to first dose of vaccine. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy. * Ability to understand and the willingness to sign a written informed consent. * Ability to adhere to the study visit schedule and all protocol requirements. * Subjects receiving cytoreductive therapy with hydroxyurea must be on a stable dose for at least 8 weeks prior to week 1. Exclusion Criteria: * Other invasive malignancy in the past 3 years except non-melanoma skin cancer, localized cured prostate cancer and early stage breast cancer on HRT. * Active autoimmune disease. * Uncontrolled serious infection. * Known immunodeficiency. * Pregnant and breastfeeding women. * Not willing to use contraception. * Current use of immunosuppressive medications including steroids. * Current JAK inhibitor use. * Current use of IFN (use of anagrelide is permitted). * Treatment with other experimental drugs within 30 days of week 1. * Treatment with any MPN directed therapy unless otherwise noted within 5 half-lives of week 1. * Any significant psychiatric/medical condition per investigators judgment.
References
Publications (0)
Data not yet available
No reference posted for this study.